Selective inhibition of FLICE-like inhibitory protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis

Molecular Medicine

Volumn 8, Issue 11, 2002, Pages 725-732

  Siegmund, Daniela ^a   Hadwiger, Philipp ^b   Pfizenmaier, Klaus ^a   Vornlocher, Hans Peter ^b   Wajant, Harald ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b Ribopharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; FLICE INHIBITORY PROTEIN; FLICE LIKE INHIBITORY PROTEIN; GREEN FLUORESCENT PROTEIN; OLIGONUCLEOTIDE; RECEPTOR PROTEIN; RIBONUCLEASE; SMALL INTERFERING RNA; TRAIL RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; ELECTROPORATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 0344321886     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402036     Document Type: Article

References (33)

1. Srivastava RK. (2001) TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546.
2. Nagane M, Huang HJ, Cavenee WK. (2001) The potential of TRAIL for cancer chemotherapy. Apoptosis 6: 191-197.
3. Ashkenazi A, Pai RC, Fong S, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155-162.
4. Walczak H, Miller RE, Ariail K, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163.
5. Jo M, Kim TH, Seol DW, et al. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6: 564-567.
6. Lawrence D, Shahrokh Z, Marsters S, et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7: 383-385.
7. Wajant H, Moosmayer D, Wuest T, et al. (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20: 4101-4106.
8. Ichikawa K, Liu W, Zhao L, et al. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7: 954-960.
9. Bodmer JL, Holler N, Reynard S, et al. (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2: 241-243.
10. Sprick MR, Weigand MA, Rieser E, et al. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
11. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620.
12. Kuang AA, Diehl G, Zhang J, Winoto A. (2000) FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275: 25065-25068.
13. Krueger A, Baumann S, Krammer PH, Kirchhoff S. (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell Biol. 21: 8247-8254.
14. Kischkel FC, Lawrence DA, Tinel A, et al. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276: 46639-46646.
15. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 98: 13884-13888.
16. Kreuz S, Siegmund D, Scheurich P, Wajant H. (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell Biol. 21: 3964-3973.
17. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. (2001) NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 21: 5299-5305.
18. Nam SY, Amoscato AA, Lee YJ. (2002) Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21: 337-346.
19. Suhara T, Mano T, Oliveira BE, Walsh K. (2001) Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ. Res. 89: 13-19.
20. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. (2001) Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J. Biol. Chem. 276: 6893-6896.
21. Gomez-Angelats M, Cidlowski JA. (2001) Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis. J. Biol. Chem. 276: 44944-44952.
22. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. (2001) MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276: 16484-16490.
23. Wang W, Prince C, Mou Y, Pollman M (2002). Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation: resistance to FasL-induced apoptosis. J. Biol. Chem. 277: 21723-21729.
24. Aoudjit F, Vuori K. (2001) Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 152: 633-643.
25. Todaro JG, Green H, Swift MR. (1966) Science 153: 1252-1254.
26. Muhlenbeck F, Schneider P, Bodmer JL, et al. (2000). J. Biol. Chem. 275: 32208-32213.
27. Vargeese C, Carter J, Yegge J, et al. (1998) Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis. Nucleic Acids Res. 26: 1046-1050.
28. Wincott F, DiRenzo A, Shaffer C, et al. (1995) Synthesis, de-protection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23: 2677-2684.
29. Weiss T, Grell M, Hessabi B, et al. (1997) Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J. Immunol. 158: 2398-2404.
30. Wajant H, Scheurich P. (2001) Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int. J. Biochem. Cell Biol. 33: 19-32.
31. Owen-Schaub LB, Zhang W, Cusack JC, et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15: 3032-3040.
32. Muller M, Strand S, Hug H, et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-413.
33. Muller M, Wilder S, Bannasch D, et al. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DANN damage by anticancer drugs. J. Exp. Med. 188: 2033-2045.